This site is intended for healthcare professionals
News

Alexion and Caelum Biosciences announce start of phase III studies of CAEL 101 in AL amyloidosis.

Read time: 1 mins
Last updated:15th Sep 2020
Published:15th Sep 2020
Condition: Light-chain Amyloidosis
Type: drug
Register free for full access to medthority.com